150 related articles for article (PubMed ID: 21997645)
1. Plasma-derived clotting factor VIII: heterogeneity evaluation in the quest for potential inhibitory-antibody stimulating factors.
D'Amici GM; Blasi B; D'Alessandro A; Vaglio S; Zolla L
Electrophoresis; 2011 Nov; 32(21):2941-50. PubMed ID: 21997645
[TBL] [Abstract][Full Text] [Related]
2. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
3. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
[TBL] [Abstract][Full Text] [Related]
5. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
6. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
[TBL] [Abstract][Full Text] [Related]
7. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
Deitcher SR; Tuller J; Johnson JA
Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
[TBL] [Abstract][Full Text] [Related]
8. Native analysis of plasma-derived clotting factor VIII concentrates: "sponge effect" and contaminants.
Blasi B; D'Amici GM; D'Alessandro A; Zolla L
Electrophoresis; 2012 Apr; 33(8):1292-8. PubMed ID: 22589109
[TBL] [Abstract][Full Text] [Related]
9. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
Johnston A
Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
[TBL] [Abstract][Full Text] [Related]
10. Functional characteristics of N8, a new recombinant FVIII.
Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
[TBL] [Abstract][Full Text] [Related]
11. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
Li X; Gabriel DA
Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
13. Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.
De Cristofaro R; De Filippis V
Biochem J; 2003 Jul; 373(Pt 2):593-601. PubMed ID: 12689334
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
16. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
17. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates.
Favaloro EJ; Bukuya M; Martinelli T; Tzouroutis J; Duncan E; Welldon K; Collecutt M; Aumann H; Thom J; Gilmore G
Thromb Haemost; 2002 Mar; 87(3):466-76. PubMed ID: 11916080
[TBL] [Abstract][Full Text] [Related]
18. Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.
Switzer ME; McKee PA
J Clin Invest; 1977 Oct; 60(4):819-28. PubMed ID: 408379
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate).
Stadler M; Gruber G; Kannicht C; Biesert L; Radomski KU; Suhartono H; Pock K; Neisser-Svae A; Weinberger J; Römisch J; Svae TE
Biologicals; 2006 Dec; 34(4):281-8. PubMed ID: 16500114
[TBL] [Abstract][Full Text] [Related]
20. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
Khrenov AV; Ananyeva NM; Saenko EL
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]